| 產(chǎn)品編號 | bs-1035R-Cy7 |
| 英文名稱1 | Rabbit Anti-CD86/Cy7 Conjugated antibody |
| 中文名稱 | Cy7標(biāo)記的CD86抗體 |
| 別 名 | CD28LG2; FUN1; LAB72; Activation B7 2 antigen; Activation B7-2 antigen 3; CD86_HUMAN; Activation B7-2 antigen; Activation B72 antigen; B lymphocyte activation antigen B7 2; B lymphocyte activation antigen B72; B-lymphocyte activation antigen B7-2 2; B-lymphocyte activation antigen B7-2; B7 2; B7 2 antigen; B7; B7-2; B7.2; B70; B72 antigen; BU63; CD 86; CD28 antigen ligand 2 2; CD28 antigen ligand 2; Cd28l2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) 1, 2; CD86 antigen; CD86 molecule; CLS1; CTLA 4 counter receptor B7 2; CTLA 4 counter receptor B7.2; CTLA-4 counter-receptor B7.2 2, 3; CTLA4 counter receptor B72; Early T-cell costimulatory molecule 1; ETC-1; FUN 1; LAB72; Ly-58; Ly58; MB7; MB7-2; Membrane glycoprotein; MGC34413; T lymphocyte activation antigen CD86; T-lymphocyte activation antigen CD86; TS/A-2. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 免疫學(xué) 微生物學(xué) 干細胞 細胞表面分子 糖蛋白 淋巴細胞 t-淋巴細胞 b-淋巴細胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, Rat, (predicted: Dog, Pig, Cow, Sheep, ) |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 31kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from the middle of human CD86 (140-175aa) |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: This gene encodes a type I membrane protein that is a member of the immunoglobulin superfamily. This protein is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of this protein with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. Alternative splicing results in several transcript variants encoding different isoforms.[provided by RefSeq, May 2011]. Function: Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation. Subunit: Homodimer. Interacts with MARCH8. Interacts with human herpesvirus 8 MIR2 protein (Probable). Interacts with adenovirus subgroup B fiber proteins and acts as a receptor for these viruses. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Tissue Specificity: Expressed by activated B-lymphocytes and monocytes. Post-translational modifications: Polyubiquitinated; which is promoted by MARCH8 and results in endocytosis and lysosomal degradation. Similarity: Contains 1 Ig-like C2-type (immunoglobulin-like) domain. Contains 1 Ig-like V-type (immunoglobulin-like) domain. Database links: Entrez Gene: 942 Human Omim: 601020 Human SwissProt: P42081 Human Unigene: 171182 Human Unigene: 229570 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. CD86是一個很重要要的輔助刺激分子，CD86作為CD28的輔助刺激分子，提供 T 細胞活化的輔助信號,它們之間的結(jié)合和隨后介導(dǎo)的信號轉(zhuǎn)導(dǎo)是 T 細胞和 APC 相互協(xié)作的重要分子基礎(chǔ)。 |
